Incyte (INCY) Stock Forecast & Price Target

Compare

1,716 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INCY Analyst Ratings

Moderate Buy

6 Buy

12 Hold

1 Sell

Based on 19 analysts giving stock ratings to

Incyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INCY Stock 12 Month Forecast

Average Price Target

$72.36

▲(7.61%Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $72.36 with a high forecast of $89.00 and a low forecast of $52.00. The average price target represents a 7.61% change from the last price of $67.24.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","90":"$90","60.75":"$60.8","70.5":"$70.5","80.25":"$80.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$89.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$52.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,60.75,70.5,80.25,90],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.31,67.13230769230769,68.95461538461538,70.77692307692308,72.59923076923077,74.42153846153846,76.24384615384615,78.06615384615385,79.88846153846154,81.71076923076923,83.53307692307692,85.35538461538462,87.17769230769231,{"y":89,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.31,65.85230769230769,66.39461538461539,66.93692307692308,67.47923076923077,68.02153846153847,68.56384615384616,69.10615384615384,69.64846153846153,70.19076923076923,70.73307692307692,71.27538461538461,71.81769230769231,{"y":72.36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.31,64.28615384615385,63.262307692307694,62.23846153846154,61.214615384615385,60.190769230769234,59.16692307692308,58.143076923076926,57.11923076923077,56.09538461538462,55.07153846153846,54.04769230769231,53.02384615384615,{"y":52,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.79,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.87,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.42,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.13,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.16,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.31,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$89.00

Average Price Target$72.36

Lowest Price Target$52.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$69

Buy

2.62%

Upside

Reiterated

05/16/25

Incyte's stock score of 71 reflects a solid financial foundation and positive earnings call outcomes, highlighting strong revenue growth and product launches. However, the high P/E ratio suggests overvaluation, and recent legal settlements could impact financials. Technical indicators present a mixed outlook, with potential short-term strength but longer-term caution. While the company remains fundamentally strong, improving profitability and managing corporate challenges will be key to enhancing stock performance.

Evan SeigermanBMO Capital

BMO Capital

$52

Sell

-22.67%

Downside

Reiterated

06/04/25

BMO Capital Reaffirms Their Sell Rating on Incyte (INCY)

Matt PhippsWilliam Blair

William Blair

―

Hold

―

Reiterated

06/04/25

Incyte's Pipeline Developments: Balancing Promising Data with Uncertainties

Unknown AnalystEvercore ISI

Not Ranked

Evercore ISI

$73

Hold

8.57%

Upside

Reiterated

06/04/25

Evercore ISI Reaffirms Their Hold Rating on Incyte (INCY)

Jessica FyeJ.P. Morgan

J.P. Morgan

$68

Hold

1.13%

Upside

Reiterated

06/03/25

Incyte (INCY) Gets a Hold from J.P. MorganJPMorgan analyst Jessica Fye reiterated a Neutral rating and $68.00 price target on Incyte (NASDAQ: INCY).

Marc FrahmTD Cowen

TD Cowen

$86

Buy

27.90%

Upside

Reiterated

06/03/25

TD Cowen Keeps Their Buy Rating on Incyte (INCY)

David LebowitzCiti

Citi

$88

Buy

30.87%

Upside

Reiterated

06/03/25

Incyte's Promising Clinical Trial Results and Favorable Safety Profile Drive Buy Rating with 34.7% Upside Potential

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

―

Hold

―

Reiterated

06/03/25

Incyte's Mixed Clinical Trial Results and Uncertainties Lead to Hold Rating

Ashwani VermaUBS

UBS

$61

Hold

-9.28%

Downside

Reiterated

06/03/25

UBS 'cautious' on Incyte's mCALR, says path to registration 'unclear' UBS 'cautious' on Incyte's mCALR, says path to registration 'unclear'

Brian AbrahamsRBC Capital

RBC Capital

$67

Hold

-0.36%

Downside

Reiterated

06/03/25

RBC says EHA late-breaking abstract shows Incyte may have drug in mCALR mAbRBC says EHA late-breaking abstract shows Incyte may have drug in mCALR mAb

Vikram PurohitMorgan Stanley

Morgan Stanley

$65→$68

Hold

1.13%

Upside

Reiterated

06/03/25

Incyte's mCALR Program: Promising Early Data but Uncertainties Remain, Justifying Hold Rating

Andrew BerensLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/03/25

Incyte's Promising Drug Pipeline and INCA33989's Strong Performance Drive Buy Rating

Srikripa DevarakondaTruist Financial

Truist Financial

$72→$73

Hold

8.57%

Upside

Reiterated

05/27/25

Truist Financial Keeps Their Hold Rating on Incyte (INCY)

Tazeen AhmadBank of America Securities

Bank of America Securities

$89

Buy

32.36%

Upside

Reiterated

05/14/25

Incyte (INCY) Receives a Buy from Bank of America Securities

Salim SyedMizuho Securities

Mizuho Securities

$77→$70

Hold

4.10%

Upside

Reiterated

05/02/25

Mizuho Securities Keeps Their Hold Rating on Incyte (INCY)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$69

Buy

2.62%

Upside

Reiterated

05/16/25

Evan SeigermanBMO Capital

BMO Capital

$52

Sell

-22.67%

Downside

Reiterated

06/04/25

BMO Capital Reaffirms Their Sell Rating on Incyte (INCY)

Matt PhippsWilliam Blair

William Blair

―

Hold

―

Reiterated

06/04/25

Incyte's Pipeline Developments: Balancing Promising Data with Uncertainties

Unknown AnalystEvercore ISI

Not Ranked

Evercore ISI

$73

Hold

8.57%

Upside

Reiterated

06/04/25

Evercore ISI Reaffirms Their Hold Rating on Incyte (INCY)

Jessica FyeJ.P. Morgan

J.P. Morgan

$68

Hold

1.13%

Upside

Reiterated

06/03/25

Incyte (INCY) Gets a Hold from J.P. MorganJPMorgan analyst Jessica Fye reiterated a Neutral rating and $68.00 price target on Incyte (NASDAQ: INCY).

Marc FrahmTD Cowen

TD Cowen

$86

Buy

27.90%

Upside

Reiterated

06/03/25

TD Cowen Keeps Their Buy Rating on Incyte (INCY)

David LebowitzCiti

Citi

$88

Buy

30.87%

Upside

Reiterated

06/03/25

Incyte's Promising Clinical Trial Results and Favorable Safety Profile Drive Buy Rating with 34.7% Upside Potential

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

―

Hold

―

Reiterated

06/03/25

Incyte's Mixed Clinical Trial Results and Uncertainties Lead to Hold Rating

Ashwani VermaUBS

UBS

$61

Hold

-9.28%

Downside

Reiterated

06/03/25

UBS 'cautious' on Incyte's mCALR, says path to registration 'unclear' UBS 'cautious' on Incyte's mCALR, says path to registration 'unclear'

Brian AbrahamsRBC Capital

RBC Capital

$67

Hold

-0.36%

Downside

Reiterated

06/03/25

RBC says EHA late-breaking abstract shows Incyte may have drug in mCALR mAbRBC says EHA late-breaking abstract shows Incyte may have drug in mCALR mAb

Vikram PurohitMorgan Stanley

Morgan Stanley

$65→$68

Hold

1.13%

Upside

Reiterated

06/03/25

Incyte's mCALR Program: Promising Early Data but Uncertainties Remain, Justifying Hold Rating

Andrew BerensLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/03/25

Incyte's Promising Drug Pipeline and INCA33989's Strong Performance Drive Buy Rating

Srikripa DevarakondaTruist Financial

Truist Financial

$72→$73

Hold

8.57%

Upside

Reiterated

05/27/25

Truist Financial Keeps Their Hold Rating on Incyte (INCY)

Tazeen AhmadBank of America Securities

Bank of America Securities

$89

Buy

32.36%

Upside

Reiterated

05/14/25

Incyte (INCY) Receives a Buy from Bank of America Securities

Salim SyedMizuho Securities

Mizuho Securities

$77→$70

Hold

4.10%

Upside

Reiterated

05/02/25

Mizuho Securities Keeps Their Hold Rating on Incyte (INCY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

1 Month

xxx

Success Rate

13/22 ratings generated profit

Average Return

+0.25%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.09% of your transactions generating a profit, with an average return of +0.25% per trade.

3 Months

xxx

Success Rate

19/34 ratings generated profit

Average Return

+2.91%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.88% of your transactions generating a profit, with an average return of +2.91% per trade.

1 Year

Marc FrahmTD Cowen

Success Rate

24/34 ratings generated profit

Average Return

+9.51%

reiterated a buy rating 4 days ago

Copying Marc Frahm's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +9.51% per trade.

2 Years

xxx

Success Rate

15/22 ratings generated profit

Average Return

+5.89%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.18% of your transactions generating a profit, with an average return of +5.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INCY Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INCY has received 10 Buy Ratings, 19 Hold Ratings, and 2 Sell Ratings. INCY average Analyst price target in the past 3 months is 72.36.

Each month's total comprises the sum of three months' worth of ratings.

INCY Financial Forecast

INCY Earnings Forecast

Next quarter’s earnings estimate for INCY is $1.40 with a range of $1.06 to $1.78. The previous quarter’s EPS was $1.16. INCY beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year INCY has Outperformed its overall industry.

INCY Sales Forecast

Next quarter’s sales forecast for INCY is $1.15B with a range of $1.13B to $1.19B. The previous quarter’s sales results were $1.05B. INCY beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year INCY has Outperformed its overall industry.

INCY Stock Forecast FAQ

What is INCY’s average 12-month price target, according to analysts?

Based on analyst ratings, Incyte Corp’s 12-month average price target is 72.36.

What is INCY’s upside potential, based on the analysts’ average price target?

Incyte Corp has 7.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INCY a Buy, Sell or Hold?

Incyte Corp has a consensus rating of Moderate Buy which is based on 6 buy ratings, 12 hold ratings and 1 sell ratings.

What is Incyte Corp’s price target?

The average price target for Incyte Corp is 72.36. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $89.00 ,the lowest forecast is $52.00. The average price target represents 7.61% Increase from the current price of $67.24.

What do analysts say about Incyte Corp?

Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of INCY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Incyte (INCY) Stock Forecast & Price Target

INCY Analyst Ratings

INCY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Incyte

INCY Analyst Recommendation Trends

INCY Financial Forecast

INCY Earnings Forecast

INCY Sales Forecast

INCY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts